Hormonal replacement therapy in an animal model with chronic renal failure and ovariectomy: Biochemical and densitometric study

Hormonal replacement therapy in an animal model with chronic renal failure and ovariectomy: Biochemical and densitometric study.BackgroundIn spite of estrogen replacement therapy being extensively used in clinical and experimental studies without renal impairment, there are no long-term studies concerning estrogen replacement in chronic renal failure.MethodsIn this experimental study, six groups of nephrectomized and ovariectomized animals were treated with different doses of 17β-estradiol, alone or in combination with calcitriol, to evaluate the effect of these treatments on bone metabolism.ResultsBiochemical results showed that estrogen alone did not have any effect neither on calcium nor on PTH serum levels. By contrast, in the groups treated with calcitriol, the levels of serum calcium were significantly higher, and the levels of iPTH were significantly lower than those observed in the control group. Animals receiving the combined treatment with estrogen and calcitriol showed the greater gain in uterus weight and a better bone mineral density at the lumbar site and the proximal and distal tibia sites.ConclusionThe combination of estrogen and calcitriol is the most effective therapy to prevent bone mass loss in animals with chronic renal failure and estrogen deprivation

The spectrum of renal osteodystrophy in Argentina [Espectro bioquímico e histológico de la osteodistrofia renal en Argentina]

Between 1994-2001 we have performed 57 bone biopsies for diagnostic purposes in symptomatic CRF patients. We analyzed here 52 samples where the material was optimal for study, and divided them into 2 periods according to when the biopsy was performed: 1994-1996 and 1997-2001, to verify changes in the spectrum of renal osteodystrophy. Mean serum values were: serum calcium 9.9 ± 1.8 mg/dl, phosphate 5.8 ± 3.2 mg/dl, alkaline phosphatase 693.9 ± 968.9 UI/L, iPTH 562.0 ± 598.5 pg/ml, serum aluminum 65.7 ± 79.3 ug/L and bone aluminum 22.8 ± 22.4 ug/g. Hyperparathyroidism was the most common histological diagnosis as severe in 13 patients (25%), or as mild in 14 (27%). Ten patients had osteomalacia (19%), adynamic bone disease was diagnosed in 5 (9.6%) and mixed renal osteodystrophy in 10 (19.2%). Low bone turnover patients showed higher bone and serum aluminum than high bone turnover patients. We observed a relative increment in high turnover bone disease in the later period (1997-2001) without changes in low turnover bone disease. These data showed a high prevalence of hyperparathyroidism and aluminumrelated low turnover bone disease, with no significant changes between the two time-periods analyzed here.Fil: Douthat, Walter Guillermo. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Garay, Gabriela. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: De Arteaga, Javier. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Fernández Martín, J.L. Universidad de Oviedo. Servicio de Metabolismo Óseo y Mineral, Instituto Reina Sodía de Investigación, Hospital Universitario Central de Asturias; EspañaFil: Cannata Andía, J.B. Universidad de Oviedo. Servicio de Metabolismo Óseo y Mineral, Instituto Reina Sodía de Investigación, Hospital Universitario Central de Asturias; EspañaFil: Massari, Pablo U. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; Argentin

Osteoporosis management in hematologic stem cell transplant recipients: Executive summary

Background: Treatment advances have reduced the adverse events associated with hematopoietic stem cell transplant (HSCT) and led to an increased number of transplants performed. HSCT patients are living longer with concerns on long-term outcomes. Bone fragility and fracture are at the forefront for long-term morbidities post-HSCT. Results: In HSCT recipients, evidence has accumulated to support recommendations for more extensive monitoring of bone fragility and more appropriate administration of osteoporosis pharmacotherapies for patients at high risk of bone loss and/or fracture. Conclusion: This executive summary reports and summarizes the main recommendations published previously, including bone assessment, dietary and lifestyle recommendations and osteoporosis medication.SCOPUS: re.jinfo:eu-repo/semantics/publishe

Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

International audienc